Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Cecchi I, Arias de la Rosa I, Menegatti E, Roccatello D, Collantes-Estevez E, Lopez-Pedrera C, et al
De-escalation strategies in HER2positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel
Check out the articles below to learn more
Media Contact En Haus Communications Mark Holcomb | [email protected] SOURCE Neurogan Health
US$ 23.51
US$ 23.61
US$ 21.99
US$ 22.55
US$ 27.63
US$ 22.75
US$ 22.46
